Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Alphamab's $100m Series A Continues Theme Of Big Investments In China Biopharma

Executive Summary

The Suzhou-based drug developer brings in new cash as US venture deals take a holiday. Also, France's Genfit may go public in the US, Taiwan Liposome launches its IPO, and Bioblast's strategic review ends in a reverse merger.

Advertisement

Related Content

Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public
Strong Innovent IPO Restoring Faith In HK Biotech Listings?
Finance Watch: Global Ventures Step Into The Spotlight As The US Takes A Breather
Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Venture Funding Deals: Two Companies With China Ties Raise $260m Each
IPO Update: Returns Halved As Two Biopharmas Go Public In April; Unity Is May's First
Hong Kong Ushers in 'New Era' For Bioventures As Listing Rules Eased
Venture Funding Deals: From ADC To Y-mAbs, Capital Flows For New Platforms, Novel Approaches
Genfit May Be Gaining An Edge In NASH Race
Green Shoots: Pharma Investments In Early Innovation Support Biotech Growth

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel